Low-grade Endometrial Adenocarcinoma A Diagnostic Algorithm for Distinguishing Atypical Endometrial Hyperplasia, and Other Benign (and Malignant) Mimics

被引:27
|
作者
McKenney, Levse K. [1 ]
Longacre, Teri A. [1 ]
机构
[1] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
关键词
endometrial adenocarcinoma; atypical endometrial hyperplasia; atypical polypoid adenomyoma; well-differentiated endometrial adenocarcinoma; endometrial metaplasia; endometrial hyperplasia; endometrium; endometrioid; hyperplasia; adenocarcinoma; WELL-DIFFERENTIATED CARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; CORD-LIKE ELEMENTS; POLYPOID ADENOMYOMA; ENDOCERVICAL ADENOCARCINOMA; CLINICOPATHOLOGIC ANALYSIS; MICROGLANDULAR HYPERPLASIA; MULLERIAN ADENOSARCOMA; SYNCYTIAL CHANGE; UTERINE CORPUS;
D O I
10.1097/PAP.0b013e3181919e15
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The distinction between endometrial hyperplasia and well-differentiated adenocarcinoma of the endometrium continues to be a difficult differential diagnosis in Surgical pathology. Evidence-based diagnostic criteria for well-differentiated endometrial adenocarcinoma focus oil histologic features that predict myoinvasion in the hysterectomy specimen. Only 2 diagnostic criteria with significant power aid in this distinction: complex glandular architectural patterns (glandular confluence, intraglandular complexity, and hierarchical papillary architecture) and marked cytologic atypia beyond that typically defined as atypical hyperplasia (ie. prominent macronucleoli visible at low power and marked nuclear pleomorphism). Application or these 2 criteria in problematic endometrial proliferations allows stratification of patients into 3 risk categories: very low risk ( < 0.05% risk or myoinvasion at hysterectomy) complex atypical hyperplasia; intermediate risk (5.5% risk of myoinvasion at hysterectomy) = complex atypical hyperplasia, cannot exclude well-differentiated adenocarcinoma (borderline); and high risk (20% risk of myoinvasion Lit hysterectomy) = well-differentiated adenocarcinoma. in order to optimize the use of these diagnostic criteria, a variety of gland forming lesions that may mimic well-differentiated endometrioid. adenocarcinoma must first be excluded. In addition, unusual morphologic patterns of low-grade endometrioid adenocarcinoma should be recognized, as they may cause confusion with other, higher grade (and therefore, more, clinically aggressive) endometrial processes,
引用
收藏
页码:1 / 22
页数:22
相关论文
共 19 条
  • [11] Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy
    Gunderson, Camille C.
    Dutta, Sonia
    Fader, Amanda Nickles
    Maniar, Kruti P.
    Nasseri-Nik, Niloo
    Bristow, Robert E.
    Diaz-Montes, Teresa P.
    Palermo, Robert
    Kurman, Robert J.
    GYNECOLOGIC ONCOLOGY, 2014, 132 (01) : 33 - 37
  • [12] Differences in the structural features of atypical adenomatous hyperplasia and low-grade prostatic adenocarcinoma
    Midi, Ahmet
    Tecimer, Tulay
    Bozkurt, Suheyla
    Ozkan, Naziye
    INDIAN JOURNAL OF UROLOGY, 2008, 24 (02) : 169 - 177
  • [13] Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy
    Penner, Kristine R.
    Dorigo, Oliver
    Aoyama, Chisa
    Ostrzega, Nora
    Balzer, Bonnie L.
    Rao, Jianyu
    Walsh, Christine S.
    Cass, Ilana
    Holschneider, Christine H.
    GYNECOLOGIC ONCOLOGY, 2012, 124 (03) : 542 - 548
  • [14] Predictive Value of 16α-[18F]-Fluoro-17β-Estradiol PET as a Biomarker of Progestin Therapy Resistance in Patients With Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer
    Yamada, Shizuka
    Tsuyoshi, Hideaki
    Tsujikawa, Tetsuya
    Okazawa, Hidehiko
    Yoshida, Yoshio
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (07) : 574 - 575
  • [15] Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin
    Simpson, Andrea N.
    Feigenberg, Tomer
    Clarke, Blaise A.
    Gien, Lilian T.
    Ismiil, Nadia
    Laframboise, Stephane
    Massey, Christine
    Ferguson, Sarah E.
    GYNECOLOGIC ONCOLOGY, 2014, 133 (02) : 229 - 233
  • [16] Low grade endometrial endometrioid adenocarcinoma: A review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features
    Lucas, Elena
    Carrick, Kelley S.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2022, 39 (03) : 159 - 175
  • [17] Low-grade, Low-stage Endometrioid Endometrial Adenocarcinoma: A Clinicopathologic Analysis of 324 Cases Focusing on Frequency and Pattern of Myoinvasion
    Quick, Charles M.
    May, Taymaa
    Horowitz, Neil S.
    Nucci, Marisa R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2012, 31 (04) : 337 - 343
  • [18] Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients
    Zhou Rong
    Yang Yuan
    Lu Qun
    Wang Jianliu
    Miao Yali
    Wang Shijun
    Wang Zhiqi
    Zhao Chao
    Wei Lihui
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 424 - 428
  • [19] Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer
    Sengal, Asmerom T.
    Smith, Deborah
    Rogers, Rebecca
    Snell, Cameron E.
    Williams, Elizabeth D.
    Pollock, Pamela M.
    CANCERS, 2021, 13 (07)